Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02227732
Other study ID # CS-IS-VH-13-001
Secondary ID CI20130054
Status Completed
Phase N/A
First received
Last updated
Start date April 2014
Est. completion date May 2015

Study information

Verified date January 2021
Source CareFusion
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a new catheter is safe and effective in treating malignant pleural effusions.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subject is = 18 years old. 2. Subject has a symptomatic malignant pleural effusion requiring intervention. For an effusion to be defined as malignant, at least one of the following must be true: - There is histocytological confirmation of pleural malignancy - The effusion is an exudate (as per Light's criteria) in the context of histocytologically proven malignancy elsewhere, with no other clear cause for fluid identified 3. Subject has a history of at least one ipsilateral pleural effusion causing dyspnoea that responded to thoracentesis where the lung expanded and the dyspnoea was relieved. 4. Subject is willing and able to provide written informed consent. 5. Subject is willing and able to meet all study requirements, including attending follow-up visits or receiving trial-related telephone calls. 6. There is sufficient fluid on thoracic ultrasound to allow safe insertion of an indwelling pleural catheter 7. Negative pregnancy test if appropriate Exclusion Criteria: 1. Subject has significant trapped lung (>20%), or a proximal bronchial obstruction which is likely to lead to trapped lung. 2. Subject has a Karnofsky score of less than 50, or a WHO/ECOG performance status of 3* or more. 3. Subject is pregnant, planning to become pregnant, or is lactating. 4. Subject has a history of empyema. 5. Subject has a history of chylothorax. 6. Subject has an uncorrected coagulopathy. 7. Subject is allergic to device materials. 8. Subject has evidence, in the opinion of the Chief Investigator, of either on-going systemic or pleural infection. 9. Subject has had a lobectomy or pneumonectomy on the side of the effusion. 10. Subject has undergone a previous attempt at pleurodesis which has failed. 11. Subject has previously been diagnosed with a serious immunodeficiency disorder. 12. Subject has bilateral pleural effusions, with both being at least moderate in size (greater than 1/3 of the hemithorax on chest x-ray). 13. Subject has evidence of fluid loculation such that attempts at pleurodesis are likely to be futile. 14. Subject has a mediastinal shift of =2cm toward the side of the effusion. 15. Subject is receiving concurrent intrapleural chemotherapy or radiation therapy to the ipsilateral chest. 16. Subject has any clinical condition, diagnosis, or social circumstance that, in the opinion of the Chief Investigator, would mean participation in the study would be contraindicated. 17. Subject has no access to a telephone 18. No details of blood values (full blood count, clotting screen, urea and electrolytes, liver function) from within the last 10 days * Patients who have a performance status of 3 may be considered for the trial if the removal of their fluid would likely improve their performance score by 1 or more.

Study Design


Intervention

Device:
New Indwelling Pleural Catheter
Placement of an indwelling catheter in the pleural space. Drainage of effusions until resolution.

Locations

Country Name City State
United Kingdom Southmead Hospital - Academic Resporatory Unit Westbury on Severn Bristol

Sponsors (1)

Lead Sponsor Collaborator
CareFusion

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Breathlesness 14, 28, 60 days
Other Chest Pain 14, 28, 60 days
Other Time to pleurodesis 14, 28, 60 days
Other Quality of Life 14, 28, 60 days
Other Need for further pleural intervention post catheter removal 60 days
Primary Device -related safety and the number of adverse events. 28 days post catheter insertion
Secondary pleurodesis success Assessed by chest x-ray, thorachic ultrasound, and confirmation the catheter is patent. 14 days
Secondary Pleurodesis success Assessed by chest x-ray, thoracic ultrasound and confirmaiton the catheter is patent. 28 days
Secondary pleurodesis success Assessed by chest x-ray, thoracic ultrasound and confirmaiton the catheter is patent. 60 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05543330 - A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC Phase 1/Phase 2
Completed NCT00758316 - A Prospective, Randomized Controlled Trial for a Rapid Pleurodesis Protocol for the Management of Pleural Effusions Phase 3
Completed NCT03869697 - Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions Phase 1
Enrolling by invitation NCT02092155 - Biomarker Levels During Indwelling Pleural cAtheter Sample Testing
Recruiting NCT00430664 - A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis N/A
Completed NCT00188474 - A Quality of Life Study re Management of Malignant Pleural Effusions N/A
Terminated NCT02623959 - Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis Phase 4